The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1606
ISSUE1606
September 7, 2020
Drugs for COPD
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for COPD
September 7, 2020 (Issue: 1606)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several guidelines
and review articles on COPD treatment...more
- GOLD. Global strategy for the diagnosis, management and prevention of COPD 2020 report. Available at www.goldcopd.org. Accessed August 27, 2020.
- L Nici et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201:e56.
- BR Celli and JA Wedzicha. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med 2019; 381:1257.
- CM Riley and FC Sciurba. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA 2019; 321:786.
- WW Labaki and SR Rosenberg. Chronic obstructive pulmonary disease. Ann Intern Med 2020;173:ITC17.
- Drugs for smoking cessation. Med Lett Drugs Ther 2019; 61:105.
- Influenza vaccine for 2019-2020. Med Lett Drugs Ther 2019; 61:161.
- S Mulpuru et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest 2019; 155:69.
- F Froes et al. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis 2017; 12:3457.
- CDC. Pneumococcal vaccine timing for adults. June 25, 2020. Available at: www.cdc.gov/pneumococcal/vaccination.html. Accessed August 27, 2020.
- B McCarthy et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 2:CD003793.
- DP Tashkin et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.
- M Decramer et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171.
- Aclidinium bromide (Tudorza Pressair) for COPD. Med Lett Drugs Ther 2012; 54:99.
- Seebri Neohaler and Utibron Neohaler for COPD. Med Lett Drugs Ther 2016; 58:39.
- Umeclidinium (Incruse Ellipta) for COPD. Med Lett Drugs Ther 2015; 57:63.
- Revefenacin (Yupelri) for COPD. Med Lett Drugs Ther 2019; 61:14.
- S Singh et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439.
- K MC Verhamme et al. Use of tiotropium Respimat soft mist inhaler versus Handihaler and mortality in patients with COPD. Eur Respir J 2013; 42:606.
- S Singh et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342:d3215.
- MT Wang et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med 2018; 178:229.
- B Celli et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20.
- RA Wise et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491.
- RA Wise et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA 2019; 321:1693.
- KM Kew et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 10:CD010177.
- M Lipari et al. Dual-versus mono-bronchodilator therapy in moderate to severe COPD: a meta-analysis. Annals Pharmacother 2020; 54:1232.
- HA Farne and CJ Cates. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 10:CD008989.
- H Ni et al. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; 12:CD011594.
- LJ Nannini et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829.
- KM Kew and A Seniukovich. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3:CD010115.
- JA Wedzicha et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016; 374:2222.
- S Suissa et al. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest 2019; 155:1158.
- DA Lipson et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378:1671.
- A Papi et al. Extrafine inhaled triple therapy versus dual bronchodilatortherapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomized controlled trial. Lancet 2018; 391:1076.
- DA Lipson et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201:1508.
- KF Rabe et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383:35.
- H Magnussen et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371:1285.
- H Watz et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4:390.
- KR Chapman et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018; 198:329.
- Roflumilast (Daliresp) for COPD. Med Lett Drugs Ther 2011; 53:59.
- PMA Calverley et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685.
- J Chong et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 11:CD002309.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RK Albert et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689.
- S Uzun et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2:361.
- RL Woosley et al. QT drugs list. Available at: www.crediblemeds.org. Accessed August 27, 2020.
- PJ Barnes. Theophylline. Am J Respir Crit Care Med 2013; 188:901.
- G Devereux et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA 2018; 320:1548.
- JK Stoller et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. CHEST 2010; 138:179.
- Long-Term Oxygen Treatment Trial Research Group et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016; 375:1617.
- CA Verberkt et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med 2020 August 17 (epub).
- EW Widera. The role of opioids in patients with chronic obstructive pulmonary disease and chronic breathlessness. JAMA Intern Med 2020 August 17 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for COPD
Article code: 1606a
Article code: 1606a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.